AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29912580 — intervention group
Group type: EXPERIMENTAL
Intervention: Pacifier group (PG)
Number of subjects: 90
Study 29912580 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 90
Study 27288694 — intervention group
Group type: EXPERIMENTAL
Intervention: Xiao procedure plus spinal cord detethering
Number of subjects: 20
Study 27288694 — intervention group
Group type: COMPARATOR
Intervention: Spinal cord detethering only
Number of subjects: 20
Study 25538330 — intervention group
Group type: EXPERIMENTAL
Intervention: Silodosin 8 mg once daily after dinner for 12 weeks
Number of subjects: 53
Study 25538330 — intervention group
Group type: COMPARATOR
Intervention: Tamsulosin 0.4 mg controlled release once daily for 12 weeks
Number of subjects: 53
Study 22687869 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide (group Exe, n = 13)
Number of subjects: 31
Study 22687869 — intervention group
Group type: COMPARATOR
Intervention: Glimepiride (group Glm, n = 18)
Number of subjects: 31
Study 20814040 — intervention group
Group type: EXPERIMENTAL
Intervention: Critical Power (CP) in children (W * kg(‐1))
Number of subjects: 0
Study 20814040 — intervention group
Group type: EXPERIMENTAL
Intervention: Anaerobic Work Capacity (AWC) in children (J * kg(‐1))
Number of subjects: 0
Study 20814040 — intervention group
Group type: EXPERIMENTAL
Intervention: AWC in children (J * kg(‐1))
Number of subjects: 0
Study 20814040 — intervention group
Group type: EXPERIMENTAL
Intervention: CP (%MAP) in children
Number of subjects: 0
Study 20814040 — intervention group
Group type: EXPERIMENTAL
Intervention: CP (%MAP and W * kg(‐1)) and AWC (J * kg(‐1))
Number of subjects: 0
Study 20814040 — intervention group
Group type: EXPERIMENTAL
Intervention: AWC (J * kg(‐1))
Number of subjects: 0
Study 17511244 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive mood group
Number of subjects: 51
Study 17511244 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative mood group
Number of subjects: 51
Study 17511244 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutral mood group
Number of subjects: 51
Study 16566410 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 11762414 — intervention group
Group type: EXPERIMENTAL
Intervention: Radioimmunotherapy (RIT)
Number of subjects: 0
Study 11762414 — intervention group
Group type: COMPARATOR
Intervention: Unlabeled antibody therapy
Number of subjects: 0
Study 9039930 — intervention group
Group type: EXPERIMENTAL
Intervention: Portal vein flush, no vena caval venting (Group 1)
Number of subjects: 100
Study 9039930 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatic arterial flush, no vena caval venting (Group 2)
Number of subjects: 100
Study 9039930 — intervention group
Group type: EXPERIMENTAL
Intervention: Portal vein flush with vena caval venting (Group 3)
Number of subjects: 100
Study 9039930 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatic artery flush with vena caval venting (Group 4)
Number of subjects: 100
Study 9039930 — intervention group
Group type: COMPARATOR
Intervention: All groups combined
Number of subjects: 100
Study 8173919 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Number of subjects: 100
Study 8173919 — intervention group
Group type: COMPARATOR
Intervention: Lignocaine
Number of subjects: 100
Study 8173919 — intervention group
Group type: COMPARATOR
Intervention: Hyaluronidase and bupivacaine
Number of subjects: 100
Study 3192867 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm humid air during recovery
Number of subjects: 20
Study 3192867 — intervention group
Group type: COMPARATOR
Intervention: Warm dry air during recovery
Number of subjects: 20
Study 2252531 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined azathioprine and thymostimulin administration
Number of subjects: 45
Study 2252531 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (Control)
Number of subjects: 45
Study 2252531 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients in remission (after stopping treatment)
Number of subjects: 45
Study 2252531 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients receiving azathioprine or thymostimulin alone
Number of subjects: 45
Study 2252531 — intervention group
Group type: EXPERIMENTAL
Intervention: C-peptide levels in patients with remission
Number of subjects: 45
Study 2252531 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin-2 production in patients in remission
Number of subjects: 45
Study 2252531 — intervention group
Group type: EXPERIMENTAL
Intervention: Time of beginning immunotherapy after onset of diabetes
Number of subjects: 45
Study 2252531 — intervention group
Group type: EXPERIMENTAL
Intervention: Age of patients
Number of subjects: 45
Study 908936 — intervention group
Group type: EXPERIMENTAL
Intervention: Common carotid ligation
Number of subjects: 60
Study 908936 — intervention group
Group type: COMPARATOR
Intervention: Bed rest (conservative treatment)
Number of subjects: 60
Study 31755989 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative oral corticosteroids (OCS) in descending doses plus nasal douching over a period of 4 weeks
Number of subjects: 70
Study 31755989 — intervention group
Group type: COMPARATOR
Intervention: Nasal douching only
Number of subjects: 70
Study 31390037 — intervention group
Group type: EXPERIMENTAL
Intervention: TECH‐N intervention (text-messaging support and community health nurse visit within 5 days of diagnosis)
Number of subjects: 286
Study 31390037 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 286
Study 31390037 — intervention group
Group type: EXPERIMENTAL
Intervention: TECH‐N intervention
Number of subjects: 286
Study 27403926 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative condition (n = 60)
Number of subjects: 120
Study 27403926 — intervention group
Group type: COMPARATOR
Intervention: Individual condition (n = 60)
Number of subjects: 120
Study 27403926 — intervention group
Group type: COMPARATOR
Intervention: Collaborative and individual conditions
Number of subjects: 120
Study 25781537 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based strength training (HBST) for 16 weeks, twice weekly (n=15)
Number of subjects: 26
Study 25781537 — intervention group
Group type: COMPARATOR
Intervention: Control group (C; n=15)
Number of subjects: 26
Study 23348398 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 23348398 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole 400 mg
Number of subjects: 40
Study 23348398 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole 800 mg
Number of subjects: 40
Study 23348398 — intervention group
Group type: EXPERIMENTAL
Intervention: Dutasteride 2.5 mg
Number of subjects: 40
Study 23348398 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrazole 1 mg
Number of subjects: 40
Study 23193870 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid White
Number of subjects: 50
Study 23193870 — intervention group
Group type: EXPERIMENTAL
Intervention: Absolute White
Number of subjects: 50
Study 23193870 — intervention group
Group type: EXPERIMENTAL
Intervention: Speed White
Number of subjects: 50
Study 23193870 — intervention group
Group type: EXPERIMENTAL
Intervention: White Glo
Number of subjects: 50
Study 23193870 — intervention group
Group type: COMPARATOR
Intervention: Artificial Saliva (Control)
Number of subjects: 50
Study 19567992 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEA 50 mg daily
Number of subjects: 0
Study 19567992 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 17033835 — intervention group
Group type: EXPERIMENTAL
Intervention: Balneotherapy (20-min bathing, once a day for five days per week for 3 weeks, total of 15 sessions)
Number of subjects: 24
Study 17033835 — intervention group
Group type: EXPERIMENTAL
Intervention: Balneotherapy (group 1)
Number of subjects: 24
Study 17033835 — intervention group
Group type: COMPARATOR
Intervention: No intervention (group 2)
Number of subjects: 24
Study 17033835 — intervention group
Group type: COMPARATOR
Intervention: Healthy control group (group 3)
Number of subjects: 24
Study 15309461 — intervention group
Group type: EXPERIMENTAL
Intervention: High n-6:n-3 PUFA diet (16)
Number of subjects: 29
Study 15309461 — intervention group
Group type: COMPARATOR
Intervention: Moderate n-6:n-3 PUFA diet (9)
Number of subjects: 29
Study 11304893 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Dose (LD, 2 mg/kg)
Number of subjects: 12
Study 11304893 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium Dose (MD, 4.5 mg/kg)
Number of subjects: 12
Study 11304893 — intervention group
Group type: EXPERIMENTAL
Intervention: High Dose (HD, 7 mg/kg)
Number of subjects: 12
Study 9151031 — intervention group
Group type: EXPERIMENTAL
Intervention: 43 microns heparin coated arterial line filter (Cobe Sentry)
Number of subjects: 40
Study 9151031 — intervention group
Group type: COMPARATOR
Intervention: No filtration (control group)
Number of subjects: 40
Study 7955265 — intervention group
Group type: EXPERIMENTAL
Intervention: Normothermic group (33.5 to 37 degrees C)
Number of subjects: 25
Study 7955265 — intervention group
Group type: COMPARATOR
Intervention: Cold group (28 to 30 degrees C)
Number of subjects: 25
Study 3672322 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent sequential pneumatic compression alone
Number of subjects: 78
Study 3672322 — intervention group
Group type: COMPARATOR
Intervention: Simultaneous use of graduated compression stockings and intermittent sequential pneumatic compression
Number of subjects: 78
Study 29346507 — intervention group
Group type: EXPERIMENTAL
Intervention: Afatinib (14 days before surgery)
Number of subjects: 30
Study 29346507 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 30
Study 28720032 — intervention group
Group type: EXPERIMENTAL
Intervention: EHR immunization alerts
Number of subjects: 264
Study 28720032 — intervention group
Group type: COMPARATOR
Intervention: Control group (no EHR alerts)
Number of subjects: 264
Study 25605643 — intervention group
Group type: EXPERIMENTAL
Intervention: Interval cycling followed by resistance exercise (ER)
Number of subjects: 8
Study 23013357 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin detemir (0.4 U/kg)
Number of subjects: 30
Study 23013357 — intervention group
Group type: COMPARATOR
Intervention: Neutral protamine lispro (NPL) (0.4 U/kg)
Number of subjects: 30
Study 23013357 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin detemir
Number of subjects: 30
Study 23013357 — intervention group
Group type: COMPARATOR
Intervention: Neutral protamine lispro (NPL)
Number of subjects: 30
Study 20453635 — intervention group
Group type: COMPARATOR
Intervention: Standard gemcitabine monotherapy (1250 mg/m in 20-30 min on days 1 and 8)
Number of subjects: 112
Study 20453635 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose gemcitabine in long infusion (200 mg/m in 6 h on day 1) and cisplatin (60 mg/m on day 2)
Number of subjects: 112
Study 20453635 — intervention group
Group type: COMPARATOR
Intervention: Standard gemcitabine monotherapy
Number of subjects: 112
Study 20453635 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose gemcitabine and cisplatin
Number of subjects: 112
Study 18332309 — intervention group
Group type: EXPERIMENTAL
Intervention: SNJ-1656 0.003%
Number of subjects: 81
Study 18332309 — intervention group
Group type: EXPERIMENTAL
Intervention: SNJ-1656 0.01%
Number of subjects: 81
Study 18332309 — intervention group
Group type: EXPERIMENTAL
Intervention: SNJ-1656 0.03%
Number of subjects: 81
Study 18332309 — intervention group
Group type: EXPERIMENTAL
Intervention: SNJ-1656 0.05%
Number of subjects: 81
Study 18332309 — intervention group
Group type: EXPERIMENTAL
Intervention: SNJ-1656 0.1%
Number of subjects: 81
Study 17161049 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 4687
Study 17161049 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated Heparin (UFH)
Number of subjects: 4687
Study 14573335 — intervention group
Group type: COMPARATOR
Intervention: Intensive control group (IC) with a target BP of <130/85 mm Hg (n = 71)
Number of subjects: 140
Study 14573335 — intervention group
Group type: COMPARATOR
Intervention: Moderate control group (MC) with a target BP of <140/90 mm Hg (n = 69)
Number of subjects: 140
Study 11223731 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified nutritional support (energy-rich diet planned for 10 MJ/day, 45-50% energy from fat)
Number of subjects: 42
Study 11223731 — intervention group
Group type: COMPARATOR
Intervention: Regular nutritional support (normal hospital diet planned for 8.5-9 MJ/day, 30-35% energy from fat)
Number of subjects: 42
Study 11223731 — intervention group
Group type: COMPARATOR
Intervention: Normal diet for normal-weight patients (group 3)
Number of subjects: 42
Study 9220210 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin (mean final daily dose of 2.8 mg)
Number of subjects: 160
Study 9220210 — intervention group
Group type: COMPARATOR
Intervention: Enalapril (mean final daily dose of 12.6 mg)
Number of subjects: 160
Study 8148213 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat breakfast (500 mg atovaquone)
Number of subjects: 47
Study 8148213 — intervention group
Group type: EXPERIMENTAL
Intervention: Toast with 28 g butter (LOFAT)
Number of subjects: 47
Study 8148213 — intervention group
Group type: EXPERIMENTAL
Intervention: Toast with 56 g butter (HIFAT)
Number of subjects: 47
Study 8148213 — intervention group
Group type: EXPERIMENTAL
Intervention: Aqueous suspension of atovaquone
Number of subjects: 47
Study 8148213 — intervention group
Group type: EXPERIMENTAL
Intervention: Oily solution/suspension in miglyol
Number of subjects: 47
Study 8148213 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. infusion of cholecystokinin octapeptide (CCK-OP)
Number of subjects: 47
Study 3250830 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticancer B
Number of subjects: 102
Study 3250830 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminoretinoic Ester
Number of subjects: 102
Study 3250830 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Starch)
Number of subjects: 102
Study 3250830 — intervention group
Group type: COMPARATOR
Intervention: Normal individuals
Number of subjects: 102
Study 3250830 — intervention group
Group type: COMPARATOR
Intervention: Early esophageal cancer patients
Number of subjects: 102
Study 31200560 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (2000 IU cholecalciferol/day for three months)
Number of subjects: 92
Study 31200560 — intervention group
Group type: COMPARATOR
Intervention: No vitamin D supplementation (control group)
Number of subjects: 92
Study 28068001 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivacaftor
Number of subjects: 3
Study 28068001 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3
Study 25788001 — intervention group
Group type: EXPERIMENTAL
Intervention: Orange juice (320 mg hesperidin)
Number of subjects: 16
Study 25788001 — intervention group
Group type: EXPERIMENTAL
Intervention: Hesperidin supplement (320 mg hesperidin)
Number of subjects: 16
Study 25788001 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 16
Study 23799963 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified pre‐arrival instructions using patient's arm and nipple line as landmarks
Number of subjects: 36
Study 23799963 — intervention group
Group type: COMPARATOR
Intervention: Control group instructions: 'Kneel down beside the chest. Place one hand in the centre of the victim's chest and the other on top.'
Number of subjects: 36
Study 21561346 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumatic dilation
Number of subjects: 201
Study 21561346 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic Heller's myotomy (LHM)
Number of subjects: 201
Study 19357539 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (LMWH)
Number of subjects: 0
Study 19357539 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin (coumadin)
Number of subjects: 0
Study 19357539 — intervention group
Group type: COMPARATOR
Intervention: Nonsteroidal antiinflammatory drugs (NSAIDs) or aspirin
Number of subjects: 0
Study 16311263 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole 800 mg/day
Number of subjects: 9
Study 15656360 — intervention group
Group type: EXPERIMENTAL
Intervention: Naphcon eye drops (3 times during 15 minutes before surgery)
Number of subjects: 100
Study 15656360 — intervention group
Group type: COMPARATOR
Intervention: Control group (no Naphcon eye drops)
Number of subjects: 100
Study 10789746 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemorrhoidectomy (Group A, n = 35)
Number of subjects: 138
Study 10789746 — intervention group
Group type: EXPERIMENTAL
Intervention: Operative dilation with postoperative dilation program (Group B, n = 39)
Number of subjects: 138
Study 10789746 — intervention group
Group type: EXPERIMENTAL
Intervention: Operative dilation without postoperative program (Group C, n = 44)
Number of subjects: 138
Study 10789746 — intervention group
Group type: COMPARATOR
Intervention: Anal dilation (Group B and C)
Number of subjects: 138
Study 8752017 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 241
Study 8752017 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 241
Study 8752017 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 241
Study 1421051 — intervention group
Group type: EXPERIMENTAL
Intervention: Teicoplanin 3 mg kg-1
Number of subjects: 13
Study 1421051 — intervention group
Group type: EXPERIMENTAL
Intervention: Teicoplanin 30 mg kg-1
Number of subjects: 13
Study 4082753 — intervention group
Group type: EXPERIMENTAL
Intervention: 16 microgram dose of HBsAg vaccine
Number of subjects: 71
Study 29433376 — intervention group
Group type: EXPERIMENTAL
Intervention: Pomegranate polyphenol supplementation (1 g of polyphenols, twice per day for one week)
Number of subjects: 16
Study 29433376 — intervention group
Group type: COMPARATOR
Intervention: Placebo (lactose pills, twice per day for one week)
Number of subjects: 16
Study 29253180 — intervention group
Group type: EXPERIMENTAL
Intervention: Active music therapy intervention
Number of subjects: 40
Study 29253180 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive music therapy intervention
Number of subjects: 40
Study 26572094 — intervention group
Group type: EXPERIMENTAL
Intervention: Discussion-Based Learning (DBL)
Number of subjects: 27
Study 26572094 — intervention group
Group type: COMPARATOR
Intervention: Lecture-Based Learning (LBL)
Number of subjects: 27
Study 25454818 — intervention group
Group type: EXPERIMENTAL
Intervention: NanoGen (nanocrystalline calcium sulfate bone graft)
Number of subjects: 60
Study 25454818 — intervention group
Group type: COMPARATOR
Intervention: DentoGen (medical-grade calcium sulfate bone graft)
Number of subjects: 60
Study 22842201 — intervention group
Group type: EXPERIMENTAL
Intervention: Staining solution (coffee) with AccessCrown material
Number of subjects: 0
Study 22842201 — intervention group
Group type: EXPERIMENTAL
Intervention: Staining solution (coffee) with Structur2 SC material
Number of subjects: 0
Study 22842201 — intervention group
Group type: EXPERIMENTAL
Intervention: Staining solution (coffee)
Number of subjects: 0
Study 22842201 — intervention group
Group type: COMPARATOR
Intervention: Distilled water (control group)
Number of subjects: 0
Study 20818901 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibutramine
Number of subjects: 10744
Study 20818901 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10744
Study 17322430 — intervention group
Group type: EXPERIMENTAL
Intervention: Alumina ceramic acetabular liner
Number of subjects: 50
Study 17322430 — intervention group
Group type: COMPARATOR
Intervention: Polyethylene acetabular liner
Number of subjects: 50
Study 16353041 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticlopidine (TIC) 500 mg BID for 2 days and 250 mg BID for subsequent 5 days
Number of subjects: 56
Study 16353041 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel (CL) 300 mg on day 1 and 75 mg/day for subsequent 6 days
Number of subjects: 56
Study 16353041 — intervention group
Group type: COMPARATOR
Intervention: Ticlopidine (TIC)
Number of subjects: 56
Study 16353041 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel (CL)
Number of subjects: 56
Study 11866268 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal controls)
Number of subjects: 0
Study 11866268 — intervention group
Group type: EXPERIMENTAL
Intervention: IBS group
Number of subjects: 0
Study 11866268 — intervention group
Group type: EXPERIMENTAL
Intervention: IBD group
Number of subjects: 0
Study 10201458 — intervention group
Group type: EXPERIMENTAL
Intervention: Dicyclomine (Dic) 20 mg four times daily
Number of subjects: 15
Study 10201458 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Pla)
Number of subjects: 15
Study 9395592 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV antibody testing, counseling and education programme
Number of subjects: 508
Study 9395592 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (no intervention)
Number of subjects: 508
Study 1935475 — intervention group
Group type: EXPERIMENTAL
Intervention: CAA with reservoir and excision of the ATZ
Number of subjects: 18
Study 1935475 — intervention group
Group type: COMPARATOR
Intervention: Control group (6 controls, mean age, 65.8 years; 2 females and 4 males)
Number of subjects: 18
Study 6130078 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone
Number of subjects: 240
Study 6130078 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 240
Study 6130078 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240
Study 30717942 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial intervention programme (six 90-min educational sessions, held weekly)
Number of subjects: 108
Study 30717942 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 108
Study 28118298 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based physical activity promotion program
Number of subjects: 29
Study 28118298 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 29
Study 26911582 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous exenatide for up to 72 hours
Number of subjects: 30
Study 26911582 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (intravenous insulin)
Number of subjects: 30
Study 24795284 — intervention group
Group type: EXPERIMENTAL
Intervention: NIRS (near-infrared spectroscopy) of frontal brain started after return of spontaneous circulation (ROSC) during admission to ICU and continued until normothermia
Number of subjects: 60
Study 24795284 — intervention group
Group type: EXPERIMENTAL
Intervention: NIRS (near-infrared spectroscopy) of frontal brain
Number of subjects: 60